We use cookies for a better user experience. Read our Privacy Policy

I Agree

Industry Verticals »

All Categories

Insights »

About TMR »

Erythropoietin Drugs Market

Schedule a Call

Erythropoietin Drugs Market

Erythropoietin Drugs Market (Drug Class - Epoetin Alfa, Epoetin Beta, and Darbepoetin Alfa; Drug Type - Biologics and Biosimilar; Drug Application - Cancer, Renal Disease, Hematology, Neurology, and Others (Surgery and Wound Healing); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025

Global Erythropoietin Drugs Market: Overview

Erythropoietin drugs can be defined as naturally occurring hormone secreted from the kidney, and perform function in development of red blood cells (RBC) by stimulating the bone marrow tissues in the bone. Rising the RBC count increases the hemoglobin level in the blood stream, transport the sufficient amount of oxygen in every part of body. The market is anticipated to grow at a significant rate owing to various factors such as high return on investments, patent expiration of erythropoietin drugs, and growing focus on awareness programs by the governmental and non-governmental organizations, and tax credits and fee waivers offered by the government, among others. According to the research report, the global erythropoietin drugs market is expected to be worth US$19,379.2 mn by the end of 2025, as the market rises at a steady CAGR of 7.5% between 2017 and 2025.

erythropoietin drugs market

Cancer to Remain Critical to Escalating Demand for Erythropoietin Drugs over Forecast Period

On the basis of drug class, the market has been segmented into epoetin alfa, epoetin beta, darbepoetin alfa, others. Epoetin alfa was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues. Epoetin alfa is usually related with cancer chemotherapy and chronic renal failure. Rising the prevalence of cancer worldwide according to National institute of cancer, 1,685,210 new cases of cancer estimated in year 2016. On the basis of drug application, the market has been segmented into cancer, renal disease, hematology, neurology, others (surgery, wound healing, etc.). Cancer was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues, owing to the factors such as increasing prevalence of chronic diseases globally.

Based on drug type, the market has been segmented into biologics and biosimilars. The biologic erythropoietin drugs dominated the market in 2016 and are anticipated to remain dominant in the forecast period. This segment is anticipated to grow at a high CAGR during the forecast period owing to long drug exclusivity period, which provides manufacturers a high return on investment (ROI). On the basis of distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2016 and is anticipated to remain the dominant segment in terms of revenues in the forecast period. The online pharmacy segment is anticipated to grow at a significant high CAGR during the forecast period, owing to the factors such as increasing reach of online pharmacy to the customers, rising the internet facilities globally, and other services such as cost containment offered by online pharmacy. 

Higher Approval Rate of Erythropoietin Drugs in North America Boosts Growth of Regional Market

Geographically, the market has been segmented into five regions, including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America was the dominant region in terms of revenues in 2016 and is anticipated to remain dominant in the forecast period. The growth in the region can be attributed to the increasing approvals of erythropoietin drugs, government incentives offered for research on chronic disease such as research and development grants, drug exclusivity, tax credit and fee waivers, among others.

Europe is anticipated to be the trailing next in terms of revenues in the forecast period. This growth can be attributed to the increasing prevalence of chronic diseases in the region. Growth of the segment is led by government initiatives for cancer and other chronic disease treatment. Governments of various countries in the region are taking efforts to decrease the rate of incidence of cancer. Asia Pacific region is growing with highest CAGR value. High incidence rate of hematological diseases in countries such as India, China, Bangladesh, and Pakistan is driving the erythropoietin drugs market in Asia Pacific.

Major players in the erythropoietin drugs market include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Wockhardt Ltd., Pfizer, Inc., Biocon Ltd., Teva Pharmaceutical Industries Ltd. etc., among others.

Rising Cancer Cases to Have a Large Influence on the Growth of the Erythropoietin Drugs Market

The erythropoietin drugs market is estimated to observe considerable growth across the assessment period of 2017-2025 on the back of the rising prevalence of chronic diseases and cancer. Erythropoietin drugs are also popular for treating chemotherapy-induced anemia. Thus, all these aspects will bring good growth opportunities for the erythropoietin drugs market.

  • Erythropoietin is a hormone released by the kidney that increases the rate of red blood cell production in response to falling oxygen levels. The drugs are used for treating individuals undergoing HIV treatments or chemotherapy. The growing prevalence of HIV and cancer cases around the world will prove to be a prominent growth generator.
  • The players in the erythropoietin drugs market are involved in research and development activities. The activities help in increasing the revenues of the players in the erythropoietin drugs market. Strategic collaborations are also crucial in increasing the growth factors. These collaborations help in cementing the foothold of the players in the erythropoietin drugs market.
  • Quick approvals from the regulatory authorities will also prove to be a prominent growth generator for the erythropoietin drugs market. The development of new formulations at a rapid rate on the back of the growing cancer cases will also bring tremendous growth opportunities for the erythropoietin drugs market.
  • The coronavirus pandemic has affected the growth prospects of the erythropoietin drugs market to a substantial extent. Supply chain and logistics disruptions dented the growth opportunities across the erythropoietin drugs market extensively. The decrease in research activities due to the rising focus on COVID-19 research-related activities further had a major influence on the growth of the erythropoietin drugs market.
  • However, the relaxations in lockdown restrictions have normalized the supply chain and logistics operations, thus providing relief to the players in the erythropoietin drugs market. The relaxations will put the growth of the erythropoietin drugs market on track.

The Erythropoietin Drugs Market has been segmented as follows:

by Drug Class
  • Epoetin Alfa
  • Epoetin Beta
  • Darbepoetin Alfa
  • Others

by Drug Type
  • Biologics
  • Biosimilar

by Drug Application
  • Cancer
  • Renal Disease
  • Hematology
  • Neurology
  • Others (Surgery, Wound healing, etc.)

by Geography 
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Spain
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC Countries
    • Israel
    • South Africa
    • Rest of MEA

    Section 1 Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights 

    Section 2 Assumptions and Research Methodology

    Section 3 Executive Summary

    Section 4 Market Overview
    4.1. Introduction
            4.1.1. Product Type Definition
    4.2. Overview
    4.3. Market Dynamics 
            4.3.1. Drivers
                     4.3.1.1. Increase number of patients suffering from anemic condition
                     4.3.1.2. Increasing number of patients suffering from cancer
                     4.3.1.3. Increasing number of patients suffering from chronic kidney disease
                     4.3.1.4. Patent Expirations of Leading Erythropoietin Drugs
                     4.3.1.5. Rising demand for improved and advanced erythropoietin drugs products
                     4.3.1.6. Reimbursement policies for patients 
            4.3.2. Restraints
                     4.3.2.1. Highly priced erythropoietin drugs resulting in minimal adoption
                     4.3.2.2. High side effects of erythropoietin drugs
            4.3.3 Opportunities
    4.4. Global Erythropoietin Drugs Market Forecast
    4.5. Porter's Five Forces Analysis
    4.6. Market Outlook
    4.7. Challenges
            4.7.1. Cancer Worldwide
            4.7.2. Anaemia Worldwide
            4.7.3. Chronic Kidney Disease Worldwide
            4.7.4. Erythropoietin Pipeline Drugs
            4.7.5. Global Price of Erythropoietin Products
            4.7.6. Global Regulatory Status 
    4.8. Heat Map Analysis 
    4.9. Product Profiling for Leading Drugs
    4.10. Epoetin alfa
    4.11. Epoetin beta
    4.12. Darbepoetin alfa
    4.13. Others

    Section 5 Global Erythropoietin Drugs Market Analysis, by Drug Class
    5.1. Key Findings / Developments
    5.2. Introduction & Definition 
    5.3. Global Erythropoietin Drugs Market Value Share Analysis, by Drug Class
    5.4. Global Erythropoietin Drugs Market Forecast, by Drug Class
    5.5. Global Erythropoietin Drugs Market Analysis, by Drug Class 
            5.5.1. Epoetin Alfa
            5.5.2. Epoetin Beta        
            5.5.3. Darbepoetin Alfa
            5.5.4. Others
    5.6. Global Erythropoietin Drugs Market Attractiveness, by Drug Class

    Section 6 Global Erythropoietin Drugs Market Analysis, by Drug Type
    6.1. Key Findings / Developments
    6.2. Introduction & Definition 
    6.3. Global Erythropoietin Drugs Market Value Share Analysis, by Drug Type
    6.4. Global Erythropoietin Drugs Market Forecast, by Drug Type
    6.5. Global Erythropoietin Drugs Market Analysis, by Drug Type
            6.5.1. Biologics
            6.5.2. Biosimilar
    6.6. Global Erythropoietin Drugs Market Attractiveness, by Drug Type

    Section 7 Global Erythropoietin Drugs Market Analysis, by Drug Type
    7.1. Key Findings / Developments
    7.2. Introduction & Definition 
    7.3. Global Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
    7.4. Global Erythropoietin Drugs Market Forecast, by Distribution Channel 
    7.5. Global Erythropoietin Drugs Market Forecast, by Distribution Channel 
            7.5.1. Hospital Pharmacy
            7.5.2. Retail Pharmacy
            7.5.3. Online Pharmacy
    7.6. Global Erythropoietin Drugs Market Attractiveness, by Distribution Channel

    Section 8 Global Erythropoietin Drugs Market Analysis, by Drug Application
    8.1. Key Findings / Developments
    8.2. Introduction & Definition 
    8.3. Global Erythropoietin Drugs Market Value Share Analysis, by Drug Application
    8.4. Global Erythropoietin Drugs Market Forecast, by Drug Application 
    8.5. Global Erythropoietin Drugs Market Analysis, by Drug Application
            8.5.1. Cancer
            8.5.2. Renal Disease
            8.5.3. Hematology
            8.5.3. Neurology
            8.5.4. Others
    8.6. Global Erythropoietin Drugs Market Attractiveness, by Drug Application

    Section 9 Global Erythropoietin Drugs Market Analysis, by Region
    9.1. Global Erythropoietin Drugs Market
    9.2. Introduction 
    9.3. Global Erythropoietin Drugs Market Value Share Analysis, by Region
    9.4. Global Erythropoietin Drugs Market Forecast, by Region
    9.5. Global Erythropoietin Drugs Market Attractiveness, by Region

    Section 10 North America Erythropoietin Drugs Market Analysis
    10.1. Key Findings / Developments
    10.2. North America Erythropoietin Drugs Market Overview
    10.3. North America Erythropoietin Drugs Market Value Share Analysis, by Country
            10.3.1. U.S.
            10.3.2. Canada
    10.4. North America Erythropoietin Drugs Market Forecast, by Country
    10.5. North America Erythropoietin Drugs Market Value Share Analysis, by Drug Class
            10.5.1. Epoetin Alfa
            10.5.2. Epoetin Beta
            10.5.3. Darbepoetin Alfa
            10.5.4. Others
    10.6. North America Erythropoietin Drugs Market Forecast, by Drug Class
    10.7. North America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
            10.7.1. Hospital Pharmacy
            10.7.2. Retail Pharmacy
            10.7.3. Online Pharmacy
    10.8. North America Erythropoietin Drugs Market Forecast, by Distribution Channel
    10.9. North America Erythropoietin Drugs Market Value Share Analysis, by Drug Type
            10.9.1. Biologics
            10.9.2. Biosimilar
    10.10. North America Erythropoietin Drugs Market Forecast, by Drug Type
    10.11. North America Erythropoietin Drugs Market Value Share Analysis, by Drug Application
            10.11.1. Cancer
            10.11.2. Renal Disease        
            10.11.3. Hematology
            10.11.4. Neurology
            10.11.5. Others (Surgery, Wound healing, etc.)
    10.12. North America Erythropoietin Drugs Market Forecast, by Drug Application
    10.13. North America Erythropoietin Drugs Market Attractiveness Analysis

    Section 11 Europe Erythropoietin Drugs Market Analysis
    11.1 Key Findings / Developments
    11.2. Europe Erythropoietin Drugs Market Overview
    11.3. Europe Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
            11.3.1. Germany
            11.3.2. U.K.
            11.3.3. France
            11.3.4. Italy
            11.3.5. Spain
            11.3.6. Rest of Europe
    11.4. Europe Erythropoietin Drugs Market Forecast, by Country
    11.5. Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Class
            11.5.1. Epoetin Alfa
            11.5.2. Epoetin Beta
            11.5.3. Darbepoetin Alfa
            11.5.4. Others
    11.6. Europe Erythropoietin Drugs Market Forecast, by Drug Class
    11.7. Europe Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
            11.7.1. Hospital Pharmacy
            11.7.2. Retail Pharmacy
            11.7.3. Online Pharmacy
    11.8. Europe Erythropoietin Drugs Market Forecast, by Distribution Channel
    11.9. Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Type
            11.9.1. Biologics
            11.9.2. Biosimilar
    11.10. Europe Erythropoietin Drugs Market Forecast, by Drug Type
    11.11. Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Application
            11.11.1. Cancer        
            11.11.2. Renal Disease
            11.11.3. Hematology
            11.11.4. Neurology
            11.11.5. Others (Surgery, Wound healing, etc.)
    11.12. Europe Erythropoietin Drugs Market Forecast, by Drug Application
    11.13. Europe Erythropoietin Drugs Market Attractiveness Analysis

    Section 12 Asia Pacific Erythropoietin Drugs Market Analysis
    12.1 Key Findings / Developments
    12.2. Asia Pacific Erythropoietin Drugs Market Overview
    12.3. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
            12.3.1. Japan
            12.3.2. China
            12.3.3. India
            12.3.4. Australia & New Zealand
            12.3.5. Rest of APAC
    12.4. Asia Pacific Erythropoietin Drugs Market Forecast, by Country
    12.5. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Class
            12.5.1. Epoetin Alfa
            12.5.2. Epoetin Beta
            12.5.3. Darbepoetin Alfa
            12.5.4. Others
    12.6. Asia Pacific Erythropoietin Drugs Market Forecast, by Drug Class
    12.7. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
            12.7.1. Hospital Pharmacy
            12.7.2. Retail Pharmacy
            12.7.3. Online Pharmacy
    12.8. Asia Pacific Erythropoietin Drugs Market Forecast, by Distribution Channel
    12.9. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Type
            12.9.1. Biologics
            12.9.2. Biosimilar
    12.10. Asia Pacific Erythropoietin Drugs Market Forecast, by Drug Type
    12.11. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Application
            12.11.1. Cancer
            12.11.2. Renal Disease
            12.11.3. Hematology
            12.11.4. Neurology
            12.11.5. Others (Surgery, Wound healing, etc.)
    12.12. Asia Pacific Erythropoietin Drugs Market Forecast, by Drug Application
    12.13. Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis

    Section 13 Asia Pacific Erythropoietin Drugs Market Analysis
    13.1 Key Findings / Developments
    13.2. Latin America Erythropoietin Drugs Market Overview
    13.3. Latin America Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
            13.3.1. Brazil
            13.3.2. Mexico
            13.3.3. Rest of LA
    13.4. Latin America Erythropoietin Drugs Market Forecast, by Country
    13.5. Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Class
            13.5.1. Epoetin Alfa
            13.5.2. Epoetin Beta
            13.5.3. Darbepoetin Alfa
            13.5.4. Others
    13.6. Latin America Erythropoietin Drugs Market Forecast, by Drug Class
    13.7. Latin America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
            13.7.1. Hospital Pharmacy
            13.7.2. Retail Pharmacy
            13.7.3 Online Pharmacy
    13.8. Latin America Erythropoietin Drugs Market Forecast, by Distribution Channel
    13.9. Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Type
            13.9.1. Biologics
            13.9.2. Biosimilar
    13.10. Latin America Erythropoietin Drugs Market Forecast, by Drug Type
    13.11. Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Application
            13.11.1. Cancer
            13.11.2. Renal Disease
            13.11.3. Hematology
            13.11.4. Neurology
            13.11.5. Others (Surgery, Wound healing, etc.)
    13.12. Latin America Erythropoietin Drugs Market Forecast, by Drug Application
    13.13. Latin America Erythropoietin Drugs Market Attractiveness Analysis

    Section 14 Middle East & Africa Erythropoietin Drugs Market Analysis
    14.1. Key Findings / Developments
    14.2. Middle East & Africa Erythropoietin Drugs Market Overview
    14.3. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
            14.3.1. GCC Countries
            14.3.2. South Africa
            14.3.3. Israel
            14.3.4. Rest of MEA
    14.4. Middle East & Africa Erythropoietin Drugs Market Forecast, by Country
    14.5. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Class
            14.5.1. Epoetin Alfa
            14.5.2. Epoetin Beta
            14.5.3. Darbepoetin Alfa
            14.5.4. Others
    14.6. Middle East & Africa Erythropoietin Drugs Market Forecast, by Drug Class
    14.7. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
            14.7.1. Hospital Pharmacy
            14.7.2. Retail Pharmacy
            14.7.3 Online Pharmacy
    14.8. Middle East & Africa Erythropoietin Drugs Market Forecast, by Distribution Channel
    14.9. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Type
            14.9.1. Biologics
            14.9.2. Biosimilar
    14.10. Middle East & Africa Erythropoietin Drugs Market Forecast, by Drug Type
    14.11. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Application
            14.11.1. Cancer
            14.11.2. Renal Disease
            14.11.3. Hematology
            14.11.4. Neurology
            14.11.5. Others (Surgery, Wound healing, etc.)
    14.12. Middle East & Africa Erythropoietin Drugs Market Forecast, by Drug Application
    14.13. Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis

    List of Tables

    Table 01: Most common type of cancer with number of deaths in 2015
    Table 02: Ranking of anemia prevalence worldwide
    Table 03: Ranking of annual mortality rate by chronic kidney disease in 2013 
    Table 04: Erythropoietin Pipeline Drugs
    Table 05: Erythropoietin Stimulating Agents Price 2015-2016
    Table 06: Regulatory Status 2015-2016
    Table 07: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 08: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 09: Global Erythropoietin Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 10: Global Erythropoietin Drugs Market Value (US$ Mn) Forecast, by Drug Application, 2015–2025
    Table 11: Global Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 12: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 13: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 14: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 15: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 16: North America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2015–2025
    Table 17: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 18: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 19: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 20: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 21: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2015–2025
    Table 22: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 23: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 24: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 25: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 26: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2015–2025
    Table 27: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 28: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 29: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 30: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 31: Latin America Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2015–2025
    Table 32: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 33: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 34: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 35: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 36: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) Forecast, by Drug Application, 2015–2025

    List of Figures

    Figure 01: Global Erythropoietin Drugs Market Size (US$ Mn) and Distribution, by Geography, 2016 and 2025
    Figure 02: Global Erythropoietin Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
    Figure 03: Global Erythropoietin Drugs Market Value Share, by Drug Class (2016)
    Figure 04: Global Erythropoietin Drugs Market Value Share, by Distribution Channel (2016)
    Figure 05: Global Erythropoietin Drugs Market Value Share, by Region (2016)
    Figure 06: World cancer prevalence
    Figure 07: World anemia prevalence (Preschool age children)
    Figure 08: World chronic kidney disease prevalence 
    Figure 09: Global Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
    Figure 10: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Epoetin Alfa, 2015–2025
    Figure 11: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Epoetin Beta, 2015–2025
    Figure 12: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Darbepoetin Alfa, 2015–2025
    Figure 13: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
    Figure 14: Global Erythropoietin Drugs Market Attractiveness, by Drug Class, 2017–2025
    Figure 15: Global Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
    Figure 16: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Biologics, 2015–2025
    Figure 17: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Biosimilar, 2015–2025
    Figure 18: Global Erythropoietin Drugs Market Attractiveness, by Drug Class, 2017–2025
    Figure 19: Global Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 20: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
    Figure 21: Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
    Figure 22: Europe Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Physician’s Office Laboratories, 2015–2025
    Figure 23: Global Erythropoietin Drugs Market Attractiveness, by Distribution Channel, 2017-2025
    Figure 24: Global Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2016 and 2025
    Figure 25: Global Erythropoietin Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Cancer, 2015–2025
    Figure 26: Global Erythropoietin Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Renal Disease, 2015–2025
    Figure 27: Global Erythropoietin Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Hematology, 2015–2025
    Figure 28: Global Erythropoietin Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Neurology, 2015–2025
    Figure 29: Europe Global Erythropoietin Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 30: Global Erythropoietin Drugs Market Attractiveness, by Drug Application, 2017-2025
    Figure 31: Global Erythropoietin Drugs Market Revenue (US$ Mn) Forecast, 2015–2025
    Figure 32: Global Erythropoietin Drugs Market Value Share Analysis, by Region, 2016 and 2025
    Figure 33: Global Erythropoietin Drugs Market Attractiveness, by Region, 2017-2025
    Figure 34: North America Erythropoietin Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
    Figure 35: North America Erythropoietin Drugs Market Attractiveness Analysis, by Country, 2017–2025
    Figure 36: North America Erythropoietin Drugs Market Value Share Analysis, by Country, 2016 and 2025
    Figure 37: North America Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
    Figure 38: North America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 39: North America Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
    Figure 40: North America Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2016 and 2025
    Figure 41: North America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2017–2025
    Figure 42: North America Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 43: North America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2017–2025
    Figure 44: Europe Erythropoietin Drugs Market Size (US$ Mn) Forecast, 2015–2025
    Figure 45: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
    Figure 46: Europe Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 47: Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
    Figure 48: Europe Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 49: Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
    Figure 50: Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2016 and 2025
    Figure 51: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2017–2025
    Figure 52: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 53: Europe Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2017–2025
    Figure 54: Asia Pacific Erythropoietin Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
    Figure 55: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
    Figure 56: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 57: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
    Figure 58: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 59: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
    Figure 60: Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2016 and 2025
    Figure 61: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2017–2025
    Figure 62: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 63: Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2017–2025
    Figure 64: Latin America Erythropoietin Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
    Figure 65: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Country, 2017–2025
    Figure 66: Latin America Erythropoietin Drugs Market Value Share Analysis, by Country, 2016 and 2025
    Figure 67: Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
    Figure 68: Latin America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 69: Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
    Figure 70: Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2016 and 2025
    Figure 71: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2017–2025
    Figure 72: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 73: Latin America Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2017–2025
    Figure 74: Middle East & Africa Erythropoietin Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
    Figure 75: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
    Figure 76: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 77: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
    Figure 78: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 79: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
    Figure 80: Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Application, 2016 and 2025
    Figure 81: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Drug Type, 2017–2025
    Figure 82: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 83: Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis, by Drug Application, 2017–2025

Google translate

Copyright © Transparency Market Research, Inc. All Rights reserved